The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?

被引:99
|
作者
Kaye, Sharlene [1 ]
Darke, Shane [1 ]
机构
[1] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia
基金
英国医学研究理事会;
关键词
ADHD; attention-deficit hyperactive disorder; diversion; misuse; pharmaceutical; stimulants; DEFICIT-HYPERACTIVITY-DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SUBSTANCE-ABUSING ADOLESCENTS; ILLICIT METHYLPHENIDATE USE; NATIONAL-COMORBIDITY-SURVEY; PRESCRIPTION DRUG-ABUSE; COLLEGE-STUDENTS; NONMEDICAL USE; UNITED-STATES; YOUNG-ADULTS;
D O I
10.1111/j.1360-0443.2011.03720.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To examine the literature pertaining to the diversion and misuse of pharmaceutical stimulants. Results The evidence to date suggests that the prevalence of diversion and misuse of pharmaceutical stimulants varies across adolescent and young adult student populations, but is higher than that among the general population, with the highest prevalence found among adults with attention deficit-hyperactive disorder (ADHD) and users of other illicit drugs. Concerns that these practices have become more prevalent as a result of increased prescribing are not supported by large-scale population surveys. Information on trends in misuse in countries where there have been recent increases in prescription and consumption rates, however, is limited. Little is known about the frequency and chronicity of misuse, or the extent of associated harms, particularly among those populations, i.e. adolescents, young adult student populations, those with ADHD and illicit drug users, where abuse may be more likely to occur. Conclusions Continued monitoring of the diversion and misuse of pharmaceutical stimulants is of major clinical importance. Despite recognition of the abuse liability of these medications, there is a paucity of data on the prevalence, patterns and harms of diversion and misuse among populations where problematic use and abuse may be most likely to occur ( e. g. adolescents, young adults, illicit drug users). Comprehensive investigations of diversion and misuse among these populations should be a major research priority, as should the assessment of abuse and dependence criteria among those identified as regular users.
引用
收藏
页码:467 / 477
页数:11
相关论文
共 50 条
  • [31] Input model uncertainty: Why do we care and what should we do about it?
    Henderson, SG
    PROCEEDINGS OF THE 2003 WINTER SIMULATION CONFERENCE, VOLS 1 AND 2, 2003, : 90 - 100
  • [32] Hepatocellular adenoma: what we know, what we do not know, and why it matters
    Bioulac-Sage, Paulette
    Gouw, Annette S. H.
    Balabaud, Charles
    Sempoux, Christine
    HISTOPATHOLOGY, 2022, 80 (06) : 878 - 897
  • [33] Environmental Analysis of Telework: What We Know, and What We Do Not Know and Why
    Horvath, Arpad
    PROCEEDINGS OF THE 2010 IEEE INTERNATIONAL SYMPOSIUM ON SUSTAINABLE SYSTEMS AND TECHNOLOGY (ISSST), 2010,
  • [34] What Do We Know and What Should We Do About Fake News?
    Hitchens, Peter
    BRITISH JOURNALISM REVIEW, 2023, 34 (01) : 70 - 71
  • [35] Working with dreams in therapy: What do we know and what should we do?
    Pesant, N
    Zadra, A
    CLINICAL PSYCHOLOGY REVIEW, 2004, 24 (05) : 489 - 512
  • [36] Genetic consequences of hunting: what do we know and what should we do?
    Harris, RB
    Wall, WA
    Allendorf, FW
    WILDLIFE SOCIETY BULLETIN, 2002, 30 (02): : 634 - 643
  • [37] Multinational monkeypox outbreak: what do we know and what should we do?
    Memariani, Mojtaba
    Memariani, Hamed
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (02) : 721 - 722
  • [38] Multinational monkeypox outbreak: what do we know and what should we do?
    Mojtaba Memariani
    Hamed Memariani
    Irish Journal of Medical Science (1971 -), 2023, 192 : 721 - 722
  • [39] Alcohol and cardiovascular disease; What do we know? What should we do?
    Trevisan, M
    Dorn, J
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 1996, 6 (03) : 111 - 113
  • [40] Public reporting of health care performance data: what we know and what we should do
    Hamblin, R.
    Shuker, C.
    Stolarek, I.
    Wilson, J.
    Merry, A. F.
    NEW ZEALAND MEDICAL JOURNAL, 2016, 129 (1431) : 7 - 17